Liezl Gambe

Achieve Life Sciences (NASDAQ:ACHV) today reported its financial results for the fourth quarter and full year ended December 31, 2025, alongside a series of transformative regulatory and operational updates for its lead smoking cessation candidate, cytisinicline.

UTStarcom (NASDAQ:UTSI) today reported its unaudited financial results for the six months and full year ended December 31, 2025, revealing a challenging fiscal year defined by a significant contraction in its primary geographic markets.

Hesai Group (NASDAQ:HSAI) today announced record financial results for the fourth quarter and full year ended December 31, 2025.

Cadeler (NYSE:CDLR) today published its anual report for the fiscal year ended December 31, 2025, detailing a period of unprecedented scale and financial outperformance.

TRON DAO has expanded its artificial intelligence fund to $1 billion, targeting infrastructure for the emerging agent-driven digital economy.

Crypto investment products recorded $230 million in inflows last week, extending a four-week streak but sharply slowing after the US Federal Reserve signalled a “hawkish pause.”

Pi Network has declined to around $0.19 after a recent rally faded, reflecting broader weakness across the crypto market as Bitcoin slipped below $70,000.

Articore Group (ASX:ATG) announced a strategic acquisition aimed at accelerating the company's long-term technology roadmap.

Myer Holdings (ASX:MYR) reported total sales of $2.28 billion for the half year, a sharp 24.5% increase compared to the previous year.

Pyxis Oncology (NASDAQ:PYXS), a clinical-stage biopharmaceutical company focused on next-generation therapeutics for difficult-to-treat cancers, announced it has completed target enrollment of approximately 40 patients in the Phase 1 monotherapy dose-expansion cohort of micvotabart pelidotin (MICVO) in patients with second-line or later recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).